Shandong Weigao Group Medical Polymer Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Rinan Cong

İcra Kurulu Başkanı

CN¥4.0m

Toplam tazminat

CEO maaş yüzdesi	42.1%
CEO görev süresi	no data
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	2.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rinan Cong'un ücretlendirmesi Shandong Weigao Group Medical Polymer'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥4m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥5m	CN¥950k	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥3m	CN¥903k	CN¥2b

Tazminat ve Piyasa: Rinan 'nin toplam tazminatı ($USD 546.69K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.93M ).

Tazminat ve Kazançlar: Rinan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rinan Cong (43 yo)

no data

Görev süresi

CN¥3,990,000

Tazminat

Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jing Long	Executive Chairman of the Board & Compliance Officer	6yrs	CN¥8.27m	0.14% € 3.7m
Rinan Cong	Chief Executive Officer	no data	CN¥3.99m	0.048% € 1.2m
Junqiang Lu	Executive Director	2.5yrs	CN¥1.32m	Veri yok
Xue Feng Wu	Chief Financial Officer	7.8yrs	Veri yok	Veri yok
Xia Yan	Non-Executive Director	less than a year	Veri yok	Veri yok
Daoming Wang	Executive Director	less than a year	Veri yok	0.011% € 284.0k
Miu Ling Wong	Company Secretary	18.6yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: UK2 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jing Long	Executive Chairman of the Board & Compliance Officer	6yrs	CN¥8.27m	0.14% € 3.7m
Junqiang Lu	Executive Director	2.5yrs	CN¥1.32m	Veri yok
Xia Yan	Non-Executive Director	less than a year	Veri yok	Veri yok
Daoming Wang	Executive Director	less than a year	Veri yok	0.011% € 284.0k
Lin Chen	Non-Executive Director	3.8yrs	Veri yok	Veri yok
Hong Meng	Independent Non-Executive Director	2.3yrs	CN¥150.00k	Veri yok
Guohui Li	Independent Non-Executive Director	2.5yrs	CN¥207.00k	Veri yok
Zhengpeng Tang	Vice Chairman	3.8yrs	Veri yok	Veri yok
Meijun Gu	Chairman of the Supervisors	4.4yrs	Veri yok	Veri yok
Zhuangqiu Zhang	Employee Representative Supervisor	2.7yrs	Veri yok	Veri yok
Qiang Li	Independent Non-Executive Director	2yrs	CN¥150.00k	Veri yok
Heng Sun	Independent Non-Executive Director	less than a year	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: UK2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/27 15:41
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Shandong Weigao Group Medical Polymer Company Limited 35 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jason Mann	Barclays
Derrick Sun	BNP Paribas Securities (Asia)
Feng Qiang Sun	BOCOM International Securities Limited

Shandong Weigao Group Medical Polymer Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold €699k worth of stock

Less than half of directors are independent

Recent updates

Shandong Weigao Group Medical Polymer Company Limited Approves the Distribution of Interim Dividend for the Six Months Ended 30 June 2024, Payable on 22 November 2024

Upcoming dividend of CN¥0.092 per share

First half dividend of CN¥0.092 announced

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.27 in 1H 2023)

Shandong Weigao Group Medical Polymer Company Limited Proposes an Interim Dividend for the Six Months Ended 30 June 2024, Payable on Before 22 November 2024

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2024 Results on Aug 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Upcoming dividend of CN¥0.094 per share

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.61 in FY 2022)

Final dividend of CN¥0.094 announced

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.60 in FY 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Approves Distribution of Interim Dividend for the Six Months Ended 30 June 2023

Upcoming dividend of CN¥0.073 per share at 2.4% yield

First half 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 1H 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 24 November 2023

New minor risk - Share price stability

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2023 Results on Aug 29, 2023

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on or Before 14 July 2023

Upcoming dividend of CN¥0.079 per share at 1.5% yield

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.51 in FY 2021)

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold €699k worth of stock

Less than half of directors are independent

Now 24% undervalued

Shandong Weigao Group Medical Polymer Company Limited Announces Resignation of Wang Jinxia as an Independent Non-Executive Director of the Company, A Member of Audit Committee, A Member of Remuneration Committee, A Member of Nomination Committee and A Member of Corporate Governance Committee

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Interim Dividend for the Six Months Ended June 30, 2022, Payable on November 11, 2022

Upcoming dividend of CN¥0.086 per share

Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066) agreed to acquire Weihai Weigao Medical Materials Company Limited from Weigao Holding Company Limited for approximately RMB288.0 million.

First half 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1H 2021)

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Changes

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2022 Results on Aug 22, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Executive Appointments

Upcoming dividend of CN¥0.065 per share

Now 24% undervalued after recent price drop

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.47 in FY 2020)

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Resignations

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, Jun 06, 2022

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2020)

Shandong Weigao Group Medical Polymer Company Limited Recommends Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited to Report Q4, 2021 Results on Mar 29, 2022

Upcoming dividend of CN¥0.077 per share

First half 2021 earnings released: EPS CN¥0.27 (vs CN¥0.22 in 1H 2020)

Investor sentiment deteriorated over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on May 24, 2021

Upcoming dividend of CN¥0.068 per share

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.41 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.41 in FY 2019)

Chairman & Compliance Officer Hua Wei Zhang has left the company

Executive Vice Chairman Yi Wang has left the company

Shandong Weigao Group Medical Polymer Company Limited Approves the Appointment of Tang Zheng Peng as a Non-Executive Director of the Company

New 90-day low: €1.38

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment deteriorated over the past week

Chairman & Compliance Officer recently sold €1.5m worth of stock

Shandong Weigao Group Medical Polymer Company Limited Announces Director Changes

New 90-day low: €1.51